Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Viral Hepat ; 12(2): 186-91, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15720534

RESUMEN

Alpha-interferon (IFN) or lamivudine monotherapy are ineffective in treating chronic HBeAg positive patients with high viral load and low alanine aminotransferase (ALT) levels. We investigated whether priming lamivudine treatment might enhance the antiviral and immunostimulant action of lamivudine/IFN combination in young tolerant patients. Eleven chronic HBeAg positive patients received: 100 mg/day lamivudine for 3 months followed by IFN 5 MU/m2/tiw with lamivudine 100 mg/day for 6 months and then lamivudine alone 100 mg/day for 9 months. Quantitative hepatitis B virus (HBV)-DNA was evaluated during treatment and core-promoter, precore and polymerase HBV mutants were detected by direct sequencing at the end of therapy. Serum HBV-DNA levels dropped during lamivudine monotherapy and in combination with IFN. After IFN withdrawal, viraemia transiently increased to high levels in five of 11 (45%) patients who showed rt M204V/I lamivudine mutant resistant. Two patients cleared HBeAg without anti-HBe seroconversion. One patient presented core-promoter (A1762T/G1764A) and precore stop codon mutations. Hence, three-phase sequential combined lamivudine/IFN treatment reduced HBV-DNA serum level, but did not lead to HBeAg and HBV-DNA clearance in these highly viraemic, normal ALT patients. Lamivudine/IFN combination did not prevent the emergence of YMDD lamivudine resistance. New schedules of antiviral treatments must be evaluated in this population at risk of disease progression.


Asunto(s)
Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/diagnóstico , Hepatitis B Crónica/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Lamivudine/uso terapéutico , Adolescente , Adulto , Factores de Edad , Niño , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Virus de la Hepatitis B/efectos de los fármacos , Humanos , Interferón alfa-2 , Pruebas de Función Hepática , Masculino , Probabilidad , Estudios Prospectivos , Proteínas Recombinantes , Medición de Riesgo , Muestreo , Índice de Severidad de la Enfermedad , Estadísticas no Paramétricas , Resultado del Tratamiento
2.
Arch Stomatol (Napoli) ; 31(1): 3-14, 1990.
Artículo en Italiano | MEDLINE | ID: mdl-2291707

RESUMEN

Recent developments in surgical treatments of dentofacial deformities, regarding the modern and far-reaching views of health protection, are taken into account by the Author. He refers to the normative provisions revealing the interest of the legal health system in this pathology. He asserts the rightfulness of the treatment and the hypotheses of unlawfulness; he mentions aspects of personal identification of a patient surgically treated whose physiognomy is modified, in the light of identification regulations. Special profiles of the patient's consent and participation in options on alternative treatments are outlined; basic deontological rules are recalled as well (risks/benefits proportion, technical ability of dentist and auxiliaries, fitness of place, accurate anaesthesiological planning).


Asunto(s)
Consentimiento Informado , Maloclusión/cirugía , Cirugía Bucal/legislación & jurisprudencia , Humanos , Planificación de Atención al Paciente , Gestión de Riesgos
3.
G Ital Cardiol ; 24(8): 965-72, 1994 Aug.
Artículo en Italiano | MEDLINE | ID: mdl-7958638

RESUMEN

A homograft bank was established in 1986 at the Institute of Cardiac Surgery of the Second University of Naples. Since then 163 aortic and pulmonary homografts have been collected, and mostly used for right ventricular outflow tract reconstruction (69 at our Institution and 14 at other Italian Centers). In March 1991 free aortic homografts were first implanted in the left ventricular outflow tract in adult patients with aortic valve and/or root disease, for a total of 15 implantations with a follow-up ranging between 3 and 19 months (mean 10 months). According to the literature and our data, operative mortality for such procedure is not higher than for ordinary aortic valve replacement. With regard to mid-term failure rate and complications, homografts are to be preferred as they don't require anticoagulation. Moreover the best indication to free homograft implantation is active aortic valve endocarditis, especially when annular abscesses are present. Reinfection rate is lesser in these patients compared to those with mechanical or bioprosthetic valves because homografts have no prosthetic material, allow exclusion of abscessual cavities from blood flow and do not require the fixation of a rigid prosthetic sewing ring in an infected, friable annulus. Finally short and mid-term haemodynamic evaluations of such patients are excellent for all the aforementioned reasons as well as for the homograft non obstruction rate.


Asunto(s)
Insuficiencia de la Válvula Aórtica/cirugía , Válvula Aórtica/trasplante , Ventrículos Cardíacos/cirugía , Adolescente , Adulto , Anciano , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Factores de Tiempo , Bancos de Tejidos , Conservación de Tejido
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA